Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.44 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11584539 | 0.93 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1LMNAMAPTHPGD | |
| SCHEMBL8406500 | 0.92 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1LMNAMAPTHPGD | |
| SCHEMBL8404275 | 0.91 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1LMNAMAPTHPGD | |
| SCHEMBL8404273 | 0.91 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1LMNAMAPTHPGD | |
| SCHEMBL8406974 | 0.91 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1LMNAMAPTHPGD | |
| SCHEMBL11584813 | 0.85 | KMT2A (0.40) | SMN1; SMN2ALDH1A1LMNAMAPTHPGD | |
| SCHEMBL11511598 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1LMNAMAPTHPGD | |
| SCHEMBL17726979 | 0.80 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1LMNAMAPTHPGD | |
| SCHEMBL17726987 | 0.80 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1LMNAMAPTHPGD | |
| SCHEMBL17727027 | 0.79 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1LMNAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722199-A1 | AZOLE COMPOUND, METHOD FOR SYNTHESIZING SAID AZOLE COMPOUND, AND USE THEREOF | SHIKOKU CHEMICALS CORPORATION (JP) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024247919-A1 | AZOLE COMPOUND, METHOD FOR SYNTHESIZING SAID AZOLE COMPOUND, AND USE THEREOF | 四国化成工業株式会社 | 2024-12-05 | — | — | WO | disclosed |
| US-11680076-B2 | Triazole silane compound, method for synthesizing said compound and use thereof | SHIKOKU CHEMICALS CORPORATION (JP) | 2023-06-20 | — | — | US | disclosed |
| CN-110475782-B | Triazole silane compound, method for synthesizing the compound, and use thereof | 四国化成工业株式会社 | 2022-05-17 | — | — | CN | disclosed |
| EP-3608327-B1 | TRIAZOLE SILANE COMPOUND, METHOD FOR SYNTHESIZING SAID COMPOUND AND USE THEREOF | SHIKOKU CHEM (JP) | 2022-05-04 | — | — | EP | disclosed |
| EP-3608327-A1 | TRIAZOLE SILANE COMPOUND, METHOD FOR SYNTHESIZING SAID COMPOUND AND USE THEREOF | Shikoku Chemicals Corporation (JP) | 2020-02-12 | — | — | EP | disclosed |
| US-20200031852-A1 | TRIAZOLE SILANE COMPOUND, METHOD FOR SYNTHESIZING SAID COMPOUND AND USE THEREOF | SHIKOKU CHEMICALS CORPORATION (JP) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680076-B2 | Triazole silane compound, method for synthesizing said compound and use thereof | CYP51A1, TLK2, SIK2 | SMN1; SMN2 4822/4885ALDH1A1 1995/4885LMNA 3218/4885 |
| US-20200031852-A1 | TRIAZOLE SILANE COMPOUND, METHOD FOR SYNTHESIZING SAID COMPOUND AND USE THEREOF | SEPTIN8, SIK2, CYP51A1 | SMN1; SMN2 4784/4885ALDH1A1 1887/4885LMNA 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.